Evidence map›Paper›PMID 25236495›Full record

ArticleCancer gene therapy2014

MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis.

H Tian, D Zhang, Z Gao, H Li, B Zhang, Q Zhang, L Li, Q Cheng, D Pei, J Zheng

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Interleukin-24 in type 2 immune diseases.Frontiers in immunology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Potential Applications of NRF2 Inhibitors in Cancer Therapy.Oxidative medicine and cellular longevity · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Mechanism of Action and Applications of Interleukin 24 in Immunotherapy.International journal of molecular sciences · 2016
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

H TianLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
D ZhangLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
Z GaoLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
H LiLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
B ZhangLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
Q ZhangLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
L LiLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
Q ChengLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
D PeiLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
J ZhengLaboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, PR China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive oxygen species (ROS) have a crucial role in melanoma differentiation-associated gene-7 (MDA-7)/interleukin-24 (IL-24)-induced cancer cell apoptosis. However, cancer cell has a series of protective mechanisms to resist ROS damage. Nuclear factor erythroid 2-related factor 2 (Nrf2) activates antioxidant response element (ARE)-mediated gene expression involved in cellular protection against oxidative stress. As the Nrf2 repressor, Kelch-like ECH-associated protein-1 (Keap1) sequesters Nrf2 in cytoplasm to block Nrf2 nuclear translocation. In the present study, administration of MDA-7/IL-24 by means of tumor-selective replicating adenovirus (ZD55-IL-24) was used to investigate whether ZD55-IL-24 could attenuate Nrf2-mediated oxidative stress response in cancer cell. We found that ZD55-IL-24 effectively strengthened the association between Nrf2 and Keap1 to restrict Nrf2 nuclear translocation, thereby inhibiting ARE-dependent transcriptional response. To evaluate the detailed mechanism underlying the suppression of ZD55-IL-24 on Nrf2-mediated oxidative stress response, we further tested three different mitogen-activated protein kinase (MAPK) signaling pathways in A549 and HeLa cells transfected by ZD55-IL-24. Our data showed that ZD55-IL-24 inhibited extracellular signal-regulated kinase (ERK) signal pathway but activated p38 and c-Jun-NH2-kinase (JNK) signal pathways to exert the tumor-specific apoptosis. Moreover, ERK pathway inhibitor U0126 prevented Nrf2 phosphorylation at Ser40 to retard Nrf2 nuclear translocation, thus decreasing antioxidant gene transcription. In contrast, p38 pathway inhibitor SB203580 obviously promoted the dissociation of Nrf2 from Keap1 to promote antioxidant gene transcription. However, JNK pathway had no effect on Nrf2 subcellular localization or the association of Nrf2 with Keap1. Conclusively, our results indicate that ZD55-IL-24 inhibits Nrf2-mediated oxidative stress response not only by activating p38 signal pathway to potentiate the association of Nrf2 and Keap1 but also by suppressing ERK signal pathway to postpone Nrf2 nuclear translocation. Given the 'dark' side of Nrf2 on carcinoma cell survival and chemoresistance, our study provides a novel explanation about MDA-7/IL-24-induced cancer-specific apoptosis and therapeutic sensitization through suppression of the cytoprotective system.

Indexed as

AdenoviridaeAntioxidant Response ElementsAntioxidantsApoptosisCell Line, TumorExtracellular Signal-Regulated MAP KinasesGene Expression Regulation, NeoplasticGenetic VectorsHumansInterleukin-24InterleukinsIntracellular Signaling Peptides and ProteinsKelch-Like ECH-Associated Protein 1MAP Kinase Signaling SystemModels, BiologicalNeoplasmsAntioxidantsExtracellular Signal-Regulated MAP KinasesInterleukin-24InterleukinsIntracellular Signaling Peptides and ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2p38 Mitogen-Activated Protein KinasesReactive Oxygen Species

Identifiers

PMID25236495
OpenAlexW2014746498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.